OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Liu on the Utility of Taletrectinib in ROS1+ NSCLC

October 30th 2023

Stephen V. Liu, MD, discusses the interim analysis of the phase 2 TRUST-II trial, which is investigating the use of taletrectinib in patients with ROS1-positive non–small cell lung cancer.

Dr Janjigian on Pembrolizumab/Trastuzumab/Chemotherapy in HER2+ Gastric Cancer

October 28th 2023

Yelena Y. Janjigian, MD, discusses results from the primary progression-free survival and interim overall survival analyses of the phase 3 KEYNOTE-811 trial in patients with HER2-positive metastatic gastric or gastroesophageal junction adenocarcinoma, and contextualizes these findings with previously reported data from this trial.

Dr Le on the Efficacy of Osimertinib Plus Ramucirumab in EGFR-Mutant mNSCLC

October 28th 2023

Xiuning Le, MD, PhD, discusses findings from the interim analysis of the phase 2 RAMOSE trial in patients with TKI-naïve metastatic non–small cell lung cancer harboring EGFR mutations.

Dr Hadoux on the Efficacy of Selpercatinib in RET-Mutant Medullary Thyroid Cancer

October 27th 2023

Julien Hadoux, MD, PhD, discusses the efficacy of selpercatinib in advanced, kinase inhibitor-naïve, RET-mutant medullary thyroid cancer as seen in the phase 3 LIBRETTO-531 trial.

Dr Gross on Updated Survival Outcomes With Neoadjuvant Cemiplimab in CSCC

October 27th 2023

Neil D. Gross, MD, FACS, discusses 1-year follow-up data from a phase 2 study of neoadjuvant cemiplimab in cutaneous squamous cell carcinoma.

Dr Hanna on the FDA Approval of Toripalimab in Nasopharyngeal Carcinoma

October 27th 2023

Glenn J. Hanna, MD, discusses the significance of the FDA approval of toripalimab for patients with recurrent or metastatic nasopharyngeal carcinoma.

Dr Tarantino on Understanding the Role of ADC Payloads in Breast Cancer

October 27th 2023

Paolo Tarantino, MD, discusses the importance of understanding the role that payloads play in treatment with antibody-drug conjugates in breast cancer.

Dr Rotow on the Investigation of ABBV-637 Plus Osimertinib in EGFR-Mutated NSCLC

October 27th 2023

Julia Rotow, MD, discusses results from a first-in-human phase 1 study of the EGFR-targeting, BCL-XL–inhibiting antibody-drug conjugate ABBV-637 in combination with osimertinib in patients with relapsed/refractory, EGFR-mutated non–small cell lung cancer.

Dr Garrido-Laguna on the Mechanism of Action of RMC-6236 in KRAS-Mutant PDAC

October 27th 2023

Ignacio Garrido-Laguna, MD, PhD, MBA, discusses preliminary safety and efficacy data with the use of RMC-6236 in patients with KRAS-mutated pancreatic ductal adenocarcinoma, highlighting the ongoing investigation of this agent.

Dr Catto on the Utility of Erdafitinib in High-Risk nMIBC With FGFR Alterations

October 27th 2023

James Catto, MB, ChB, PhD, FRCS, discusses the utility of erdafitinib in patients with high-risk non–muscle-invasive bladder cancer with select FGFR alterations who have received prior treatment with Bacillus Calmette–Guérin.

Dr Choueiri on the Utility of Belzutifan/Cabozantinib in Advanced ccRCC

October 27th 2023

Toni K. Choueiri, MD, discusses findings from the phase 2 LITESPARK-003 study of belzutifan in combination with cabozantinib for patients with advanced clear cell renal cell carcinoma.

Dr Bilusic on Key Trials That Inform the Treatment of Patients With Urothelial Carcinoma

October 27th 2023

Marijo Bilusic, MD, PhD, discusses key trials in the treatment armamentarium for patients with urothelial carcinoma, as presented at the 2023 Sylvester Annual Oncology Updates Meeting.

Dr Girard on the Development of ADCs in Patients With NSCLC

October 27th 2023

Nicholas Girard, MD, PhD, discusses the evolving role of antibody-drug conjugates in the treatment of patients with non–small cell lung cancer, highlighting data from the phase 3 TROPION-Lung01 study.

Dr Mirza on the Use of Dostarlimab/Chemotherapy By Molecular Class in Endometrial Cancer

October 27th 2023

Mansoor Raza Mirza, MD, discusses treatment outcomes with the use of dostarlimab plus chemotherapy in patients with primary advanced or recurrent endometrial cancer whose disease was mismatch repair deficient/microsatellite instability–high, TP53 mutated, or had no specific molecular profile.

Dr Arbour on the Safety and Efficacy of RMC-6236 in KRAS-Mutant NSCLC

October 26th 2023

Kathryn C. Arbour, MD, discusses preliminary safety and efficacy data with the RAS inhibitor RMC-6236 in patients with KRAS-mutated non–small cell lung cancer.

Dr Berdeja on Ongoing and Planned Research Initiatives in Patients With Multiple Myeloma

October 26th 2023

Jesus Berdeja, MD, director, discusses ongoing and planned research initiatives in patients with multiple myeloma, specifically highlighting initiatives taking place at Tennessee Oncology.

Dr Hunter on the Ongoing Investigation into JAK Inhibitors in Myelofibrosis

October 26th 2023

Anthony M. Hunter, MD, discusses the evolution of JAK inhibitors in myelofibrosis, a topic that was highlighted in a presentation at the 2023 SOHO Annual Meeting.

Dr Narayan on the Evolving Treatment Paradigm in Metastatic Urothelial Carcinoma

October 26th 2023

Vivek K. Narayan, MD, MS, discusses potential avenues for treatment considerations in patients with metastatic urothelial carcinoma.

Dr Patel on the Importance of Real-World Data in Lung Cancer Treatment

October 26th 2023

Sandip P. Patel, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, expanding on the continued importance of replicating clinical trial approaches in the real-world setting.

Dr Bazhenova on Addressing Potential Gaps in the Treatment of Lung Cancer Care

October 26th 2023

Lyudmila A. Bazhenova, MD, discusses the 2023 Bridging the Gaps in Lung Cancer meeting, expanding on the hope to confirm a consensus on how to best move forward to address gaps in lung cancer care.